Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q8N8R5
UPID:
CB069_HUMAN
Alternative names:
-
Alternative UPACC:
Q8N8R5; Q8NE30
Background:
Mitochondrial protein C2orf69 plays a crucial role in the respiratory chain, a key component of cellular energy production. This protein's involvement in mitochondrial function underscores its importance in cellular metabolism and energy dynamics.
Therapeutic significance:
Linked to Combined oxidative phosphorylation deficiency 53, a disorder marked by developmental delays, liver dysfunction, and autoinflammation, C2orf69's study offers insights into novel therapeutic approaches for mitochondrial diseases.